维丙胺(Diisopropylamine Ascorbate) - 在研适应症：肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式-

作用机制-

治疗领域

消化系统疾病

在研适应症

肝炎

非在研适应症-

原研机构

亚邦医药股份有限公司

在研机构

南京制药厂有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (1982-01-01),

肝炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H23NO6

InChIKeyJNTRWMFGOGVBIA-MGMRMFRLSA-N

CAS号95512-09-7

关联

100 项与维丙胺相关的临床结果

登录后查看更多信息

100 项与维丙胺相关的转化医学

登录后查看更多信息

100 项与维丙胺相关的专利（医药）

登录后查看更多信息

2

项与维丙胺相关的文献（医药）

Yaoxue Tongbao

Stability of rivanol injection

作者: Liang, Chuankui

Rivanol (I) [1837-57-6] injections were susceptible to light, heat (100 or 121.5° for 10 min) and, to a lesser extent to O.AgNO₃, CuSO₄, MgSO₄, Ph(OAc)₂, Fe₂S₃, Na₂S and K₂CO₃ accelerated I precipitationVitamin C [50-81-7], diisopropylamine ascorbate [97401-32-6], NaHSO₃, Na₂S₂O₃, Na EDTA [7379-28-4], boric acid and Na pyrosulfite alone or in combinations did not stabilize I injections.

Hunan Yixueyuan Xuebao

Hypotensive and ganglionic blocking effects of diisopropylamine salts

作者: Li, Yuanjian ; Liu, Liying ; Tang, Xianliang ; Wang, Wanwu ; Chen, Xiu

(Iso-Pr)₂NH (I) [108-18-9] (0.42 or 1.3 mg/kg, i.v.) and equivalent amounts of its salts I nicotinate [941-01-5], I salicylate [36364-50-8], I dichloroacetate [660-27-5], I ascorbate [95512-09-7], I-HCl [819-79-4], I lactonate [95512-10-0], and I p-chlorophenoxylate [95512-11-1] had hypotensive activity in dogs and rats.The rank order of potencies was somewhat different between the 2 species, though in both cases I nicotinate was the most active.I salicylate had ganglionic blocking activity in cats, and this property may be the mechanism of the hypotensive activities of the compoundsTachyphylaxis of the hypotensive response was seen upon repeated injection of I salicylate into rats.

100 项与维丙胺相关的药物交易

登录后查看更多信息